Skip to content

Clinical trials

Dyskinesias trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Dyskinesias Clear all

173 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20003
20013
20025
20036
20046
20053
20064
20077
20084
200912
20108
201111
20125
20138
20149
20155
20165
20176
20183
20197
20208
202110
20225
20233
202412
20255
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed101
Terminated26
Unknown status18
Recruiting15
Withdrawn3
Not yet recruiting3
Suspended2
No longer available2
Active, not recruiting2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Neurological Disorders and Stroke (NINDS)13
Novartis Pharmaceuticals7
Adamas Pharmaceuticals, Inc.6
Great Lakes NeuroTechnologies Inc.6
Oregon Health and Science University6
AbbVie (prior sponsor, Abbott)5
Novartis5
CardioKinetix, Inc4
Addex Pharma S.A.3
Auspex Pharmaceuticals, Inc.3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Dyskinesias173
Parkinson Disease107
Movement Disorders29
Parkinsonian Disorders14
Tremor14
Central Nervous System Diseases13
Nervous System Diseases13
Chorea10
Neurologic Manifestations9
Hypokinesia8

Trials

Showing 1 to 25 of 173. Each trial links to its page on Pharma Observatory.

73 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.